Study of PHA-848125AC in Adult Patients With Advanced/Metastatic Solid Tumors
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this open-label, multi center, Phase I study was to determine the safety
profile of the oral compound PHA-848125AC administered according to two different schedules
of administrations to advanced/metastatic solid tumor patients. Objectives of the study were
to determine the maximum tolerated dose and the dose that can be recommended for Phase II
investigations.